Natera
Natera Files New Patent Infringement Lawsuit Against CareDx
Natera alleges that several of CareDx's organ transplant products infringe the patent underlying its Panorama NIPT assay.
Natera Q1 Revenues Rise 28 Percent on Increased Product Revenues
The firm's product revenues were up 58 percent, and it beat the analysts' average estimates on both the top and bottom lines.
In Brief This Week: Natera, Caris Life Sciences, Fulgent Genetics, Castle Biosciences, More
News items for the week of April 25, 2022
Three new studies focusing on the heart, lungs, and kidneys add to a growing body of evidence in support of donor-derived cell-free DNA as an organ health measure.
FDA Cautions of False Results From Prenatal Genetic Tests
The regulatory agency reminded the public that NIPTs are not diagnostic and that none have yet to win regulatory approval.